All AbMole products are for research use only, cannot be used for human consumption.
JZP 361 is a potent and selective reversible MAGL inhibitor (IC50 = 46 nM). Exhibits 35-fold and 150-fold higher selectivity over human FAAH and ABHD6, respectively (IC50 values are 1.79 and 7.24 μM, respectively). Displays affinity for H1 receptors (pA2 = 6.81). Exhibits no activity at cannabinoid receptors at 10 μM.
| Molecular Weight | 405.88 |
| Formula | C22H20ClN5O |
| CAS Number | 1680193-80-9 |
| Solubility (25°C) | DMSO 40.59 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Products |
|---|
| BAY-9835
BAY-9835 is a potent and orally active ADAMTS7 and ADAMTS12 antagonist with IC50s of 6 nM and 30 nM, respectively. BAY-9835 is very selective against a range of off-targets and metalloproteases. |
| Succinate/succinate receptor antagonist 1
Succinate/succinate receptor antagonist 1 is a succinate/succinate receptor antagonist. Succinate/succinate receptor antagonist 1 blocks succinate signaling in gingival tissue. Succinate/succinate receptor antagonist 1 inhibits the activation of succinate receptor 1 (SucnRl) with an IC50 value of 20 μΜ. |
| L-α-lysophosphatidylcholine (soybean)
L-α-lysophosphatidylcholine (soybean) |
| Lauroyl-L-carnitine chloride
Lauroyl-L-carnitine chloride can be used as an absorption enhancer. |
| Nicotinic acid mononucleotide triethylamine
Nicotinic acid mononucleotide triethylamine is formed from nicotinic acid (NA) via the nicotinic acid phosphoribosyltransferase in the biosynthesis of NAD+. Nicotinate mononucleotide triethylamine is a substrate for nicotinamide mononucleotide/Nicotinic acid mononucleotide adenylyltransferase. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
